ATH Shares Alterity Therapeutics Limited
ASX · ASXLast in our picks 2026-10-13 — not in the current list; analysis below is from that screen
Neurodegenerative-disease pipeline offers high-upside clinical optionality following substantial price weakness.
Future value: $0.60 (+76.47%) · 6-12 months
Signal breakdown
- ▸Clinical pipeline optionality but limited confirmed current buy signals.
- ▾Below 50-day MA (-27.36%)
- ▾Near 52-week low (1.1% of range)
- ▸~76% upside to price target
Is ATH a buy right now?
Trend: ATH is trading below the 50-day average (-35.37%), RSI 43 — neutral momentum, with a 3-month return of -50.00%.
Valuation & quality: Alterity Therapeutics Limited trades on forward P/E -0.2, PEG 1.29, price-to-book 1.35; fundamentals show net margin 0.0%, return on equity -55.0%, revenue growth -79.0% year on year.
Analyst consensus: 3 analysts have a mean 12-month price target of A$5.52 (+1981.8% vs the last close; range A$0.95 – A$10.00), consensus rating “none”.
Our screen: ACCUMULATE (score 1) — Neurodegenerative-disease pipeline offers high-upside clinical optionality following substantial price weakness.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +12.50% | +11.10% | -10.00% | +26.70% | -3.50% | -9.10% | -20.00% | -35.00% |
Fundamentals
Analyst price target
Technical signals
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease.
Sector: Healthcare · Industry: Biotechnology · Australia · 11 employees · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.